10.8.2013
EN
Official Journal of the European Union
C 233/7
Judgment of the General Court of 3 July 2013 — Cytochroma Development v OHIM — Teva Pharmaceutical Industries (ALPHAREN)
(Case T-106/12) (1)
(Community trade mark - Opposition proceedings - Application for the Community word mark ALPHAREN - Earlier national word marks ALPHA D3 - Relative ground for refusal - Compliance by OHIM with a judgment annulling a decision of its Boards of Appeal - Article 65(6) of Regulation (EC) No 207/2009 - Composition of the Boards of Appeal - Article 1(d) of Regulation (EC) No 216/96)
2013/C 233/11
Language of the case: English
Parties
Applicant: Cytochroma Development, Inc. (Saint Michael, Barbados) (represented by: S. Malynicz, Barrister, and A. Smith, Solicitor)
Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: A. Folliard-Monguiral, acting as Agent)
Other party to the proceedings before the Board of Appeal of OHIM: Teva Pharmaceutical Industries Ltd (Jerusalem, Israel)
Re:
Action brought against the decision of the First Board of Appeal of OHIM of 2 December 2011 (Case R 1235/2011-1), relating to opposition proceedings between Teva Pharmaceutical Industries Ltd and Cytochroma Development, Inc.
Operative part of the judgment
The Court:
1.
Annuls the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) of 2 December 2011 (Case R 1235/2011-1);
2.
Orders OHIM to pay the costs.
(1) OJ C 138, 12.5.2012.
Full & Egal Universal Law Academy